eXoZymes, Inc. (EXOZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, eXoZymes, Inc. (EXOZ) has a cash flow conversion efficiency ratio of -0.998x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.52 Million) by net assets ($1.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see eXoZymes, Inc. market capitalisation for the company's overall valuation and market capitalisation.
eXoZymes, Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how eXoZymes, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
eXoZymes, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of eXoZymes, Inc. ranked by their cash flow conversion efficiency. See cash flow to debt ratio of eXoZymes, Inc. to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Osteonic Co. Ltd
KQ:226400
|
0.017x |
|
Nimbus Group AB
ST:BOAT
|
0.150x |
|
CanAlaska Uranium Ltd
V:CVV
|
-0.078x |
|
Natura City Developments Tbk PT
JK:CITY
|
-0.007x |
|
Reitmans (Canada) Limited
V:RET-A
|
0.172x |
|
GP Global Power Ltd
TA:GPGB
|
-0.052x |
|
Annovis Bio Inc
NYSE:ANVS
|
-2.883x |
|
Sambu Const
KO:001470
|
-0.064x |
Annual Cash Flow Conversion Efficiency for eXoZymes, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of eXoZymes, Inc. from 2021 to 2025. View EXOZ live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.40 Million | $-6.50 Million | -1.914x | -134.48% |
| 2024-12-31 | $10.42 Million | $-8.51 Million | -0.816x | -126.56% |
| 2023-12-31 | $-384.32K | $-1.18 Million | 3.073x | +435.48% |
| 2022-12-31 | $1.37 Million | $-1.26 Million | -0.916x | +30.90% |
| 2021-12-31 | $1.20 Million | $-1.59 Million | -1.325x | -- |
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.